July 11, 2011

Sanofi Divests Dermik Dermatology Unit to Valeant Pharmaceuticals International, Inc.

- Strategic Divestiture to focus on Growth Platforms in the United States and Canada -

 

Sanofi Divests Dermik Dermatology Unit to Valeant Pharmaceuticals International, Inc.
- Strategic Divestiture to focus on Growth Platforms in the United States and Canada -

Paris, France – July 11, 2011 – Sanofi (EURONEXT: SAN and NYSE: SNY) announced today the strategic divestiture of its dermatology business, Dermik, to Valeant Pharmaceuticals International Inc. (NYSE/TSX: VRX) (“Valeant”), for a total cash consideration of US $425 million. Valeant is a pharmaceutical company focused on the neurology and dermatology therapeutic areas, based in Mississauga, Ontario, Canada.